Incyte Corporation (INCY)

CIK 0000879169 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-07-28) · 99.1
Q1-2026 8-K (2026-04-28) · 99.1
Latest FY-2025 8-K (2026-02-10) · 99.1
Q3-2025 8-K (2025-10-28) · 99.1
Q2-2025 8-K (2025-07-29) · 99.1
Q1-2025 8-K (2025-04-29) · 99.1
FY-2024 8-K (2025-02-10) · 99.1
Q3-2024 8-K (2024-10-29) · 99.1
Q2-2024 8-K (2024-07-30) · 99.1
Q1-2024 8-K (2024-04-30) · 99.1
FY-2023
FY-2023 8-K (2024-02-13) · 99.1
Q3-2023 8-K (2023-10-31) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Income
Consolidated Statements of Comprehensive Income (loss)
Consolidated Statements of Stockholders' Equity
Consolidated Statements of Stockholders' Equity (P)
Consolidated Statements of Cash Flows
Notes
Accrued and Other Current Liabilities
Acquisitions
Asset Acquisition
—
Collaborative and Other Relationships
Commitments and Contingencies
Concentrations of Credit Risk and Current Expected Credit Losses
Cybersecurity Risk Management and Strategy Disclosure
—
Employee Benefit Plans
Fair Value of Financial Instruments
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Intangible Assets and Goodwill
—
Inventory
License Agreements
Net (loss) Income Per Share
—
Net Income (loss) Per Share
—
Net Income Per Share
Organization and Business
—
Organization and Summary of Significant Accounting Policies
—
Other Comprehensive Income (loss)
Pay Vs Performance Disclosure
Property and Equipment, Net
Revenues
Segment Information
Stock Compensation
Stockholders' Equity
Subsequent Event
Summary of Significant Accounting Policies
—